PresseBox
Press release BoxID: 106290 (QIAGEN N.V.)
  • QIAGEN N.V.
  • Hulsterweg 82
  • 5912 Venlo
  • http://www.qiagen.com
  • Contact person
  • Solveigh Karola Mähler
  • +49 (2103) 29-11710

Dr. Werner Brandt and Heino von Prondzynski to Stand for

(PresseBox) (Hilden, ) QIAGEN N.V. (Nasdaq: QGEN, Frankfurt, Prime Standard: QIA), today announced, that Dr. Werner Brandt and Heino von Prondzynski agreed to be nominated for election to join QIAGEN’s Board of Supervisory Directors. Both candidates will be stand for election on QIAGEN’s Annual General Meeting being held in Venlo on June 20, 2007.

"We are very pleased to be able to announce the candidacies of Heino von Prondzynski and Dr. Werner Brandt for election to QIAGEN’s Supervisory Board," said Prof. Dr. Detlev Riesner, QIAGEN’s Chairman of the Supervisory Board. "In their roles as directors, Mr. Prondzynski and Dr. Brandt will provide invaluable insight, advice and guidance as QIAGEN’s contributions and products further expand the frontiers of science and healthcare and build value for our customers, shareholders and employees."

“We would also like to take the opportunity to thank Dr. Franz Wirtz and Dr. Heinrich Hornef for their immense contributions to helping us achieve the strong position we are in today,” he continued. “After 18 years and 7 years, respectively, as members of our Supervisory Board, both members will be retiring from the QIAGEN Supervisory Board at our Annual General Meeting. Their service to QIAGEN and our shareholders was extremely valuable.”

Heino von Prondzynski retired in 2005 from Roche (SWX: RO) as Chief Executive Officer of Roche Diagnostics and Member of the Executive Committee of the Roche Group. He brings to QIAGEN a wealth of experience as a leader in the diagnostics industry and played key roles in building the molecular diagnostics industry. Prior to joining Roche in 2000, Mr. von Prondzynski worked at Chiron, first as General Manager and Chief Executive Officer in Germany and Italy, later as President of the Vaccines Division in Emeryville/USA. Mr. von Prondzynski started his career with Bayer in Germany as sales representative and worked later in Austria and Brazil as General Manager. He studied mathematics, geography and history at Westfaelische Wilhelms University of Muenster in Germany.

Dr. Werner Brandt joined SAP (NYSE: SAP, Frankfurt/DAX: SAP) in February 2001 as Chief Financial Officer and member of the SAP Executive Board. From 1999 to 2001, he was a member of the Executive Board and Chief Financial Officer of the German-American healthcare company, Fresenius Medical Care AG (NYSE: FMS, Frankfurt/DAX: FME), where he also served as labor relations director. From 1992 to 1999, Dr. Brandt was a member of the management board of Baxter Deutschland GmbH and Vice President for European operations. In this capacity, he was responsible for Baxter's financial operations in Europe. Dr. Brandt began his career in 1981 at the former Price Waterhouse GmbH (now PricewaterhouseCoopers) in Frankfurt. Dr. Brandt completed his doctorate in business administration from the Technical University of Darmstadt, Germany, in 1991, after studying business administration at the Friedrich-Alexander-University Erlangen-Nuremberg, Germany, from 1976 to 1981.

QIAGEN N.V.

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,800 people in more than 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.